samedan logo

 
 
spacer
home > ebr > spring 2003 > signal transduction in breast cancer: silencing the cross-talk
PUBLICATIONS
European Biopharmaceutical Review

Signal Transduction in Breast Cancer: Silencing the Cross-Talk

Signal transduction pathways mediate the ability of cells to respond to hormonal and environmental stimuli. Diverse and rapid cellular responses to external stimuli may involve proliferation, differentiation, migration or programmed cell death. In the normal cell a tightly regulated cross-talk network between multiple independent and convergent pathways maintains the cell in a specific developmental and functional pathway. Aberrations in these signal transduction pathways can result in cellular transformation. Furthermore, experimental evidence suggests that pathway cross-talk augments the tumorigenic and metastatic potential of transformed cells. Additionally, cross-talk between diverse signal transduction pathways appears to play a critical role in the progression and therapeutic resistance of breast cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Frank E Jones, Department of Structural and Cellular Biology, Dr Matthew E Burow, Department of Medicine (Hematology & Medical Oncology), Department of Surgery, and Dr Steven M Hill, Department of Structural and Cellular Biology, at Tulane Cancer Center

Dr Frank E Jones undertook his post-doctoral training at Yale University within the Department of Pathology. He accepted a position as Assistant Professor at Tulane University in the Department of Structural and Cellular Biology in June 2001.

Dr Jones' research interests focus on the development of mouse models to study the molecular mechanisms contributing to metastatic breast, ovarian and prostate cancers.

Dr Matthew E Burow carried out his post-doctoral studies at the Tulane/Xavier Center for Bioenvironmental Research and was subsequently appointed as a Research Assistant Professor in the Department of Pharmacology in 2000. In 2002 Dr Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine, with an appointment as an Adjunct Assistant Professor in the Department of Surgery. His primary research interests focus on understanding the molecular mechanisms that control oestrogen receptor mediated gene expression and anti-oestrogen resistance in breast carcinoma cells, as well as the way that cell survival and apoptotic signalling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.

Dr Steven M Hill undertook his post-doctoral training at the University of Texas Health Sciences Center, San Antonio, in the Medical Oncology section of the Department of Medicine under the tutelage of the late Dr William L McGuire. Dr Hill joined Tulane University in 1989 as an Assistant Professor and is currently Professor of Structural and Cellular Biology at Tulane University Health Sciences Center and holds the Edmond and Lily Safra Chair for breast cancer research. Dr Hill's general research interests focus on defining the mechanisms of cross-talk between G-protein coupled receptor signalling pathways and steroid hormone receptor signalling pathways in breast cancer.
spacer
Dr Frank E Jones
spacer
spacer
spacer
Dr Matthew E Burow
spacer
spacer
spacer
Dr Steven M Hill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement